A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.

被引：0

作者：

Wagner, Andrew J.

Banerji, Udai

Mahipal, Amit

Somaiah, Neeta

Hirsch, Heather Anne

Fancourt, Craig

Levonas, Amy

Lam, Raymond

Meister, Amy

Kemp, Ramon Karmel

Knox, Clayton

Rose, Shelonitda

Hong, David S.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Inst Canc Res, London SW3 6JB, England

[3] Royal Marsden NHS Fdn Trust, London, England

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA

[6] Merck & Co Inc, Kenilworth, NJ USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10564

引用

页数：1